BioSpace News Archive

John McHutchison, AO, M.D., Appointed to Board of Directors Adding Significant Industry Experience and Drug Development Expertise

OPKO Health Inc. announced that the Japan Phase 3 clinical trial met its primary and secondary objectives, and demonstrated that the efficacy and safety of somatrogon administered weekly was comparable to GENOTROPIN® for injection administered once-daily as measured by annual height velocity after 12 months of treatment in treatment-naïve Japanese pre-pubertal children with GHD.

CureDuchenne Ventures, the venture funding arm of CureDuchenne, a leading global nonprofit dedicated to funding and finding a cure for Duchenne muscular dystrophy, announced the first ever CureDuchenne Ventures 2020 Pitch Contest.

Centene Corporation announced that its virtual investor meeting, scheduled for Friday, June 12, 2020, will now start 30 minutes earlier.

BioMedInnovation Aims to Address Global Shortages of Life-Saving Machines Due to COVID-19 via Manufacturing Process Independent of Commercial and Other Ventilator Supply Chains

The first days of summer mean warmer temperatures and plenty of sunlight for outdoor play.

LifeShare Blood Center deploys Biolog-id’ s Cutting-Edge Technology Providing Digital Visibility to Convalescent Plasma Containing Antibodies from Recovered COVID-19 Patients

Leading assistive technology provider Cognixion announces the launch of a revolutionary new AI-powered product with Lincare AAC, a division of Lincare Holdings Inc., and provider of oxygen and other respiratory therapy services to patients nationwide.

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it is scheduled to join the U.S. broad-market Russell 3000 Index when FTSE Russell, a leading global index provider, reconstitutes its 2020 indices after the markets clo

Resverlogix Corp. is pleased to announce key data from its BETonMACE clinical trial in pre-specified stage 3 chronic kidney disease patients.